Insider trading

Period: 120 months Stock: ONC + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

455 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

455 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

455 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

455 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
455 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
455 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

455 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
10 May 2021
Wang Xiaodong Director
Sold, plan not stated 4×
$1.02M 3,394 at 300.46
100%
Sold half or more
3 May 2021
Wu Xiaobin President, COO & GM China
Sold, plan not stated
$2.30M 6,715 at 343.00
100%
Sold half or more
29 Apr 2021
Huang Jane CMO, Hematology
Sold, plan not stated 6×
$532.39K 1,500 at 354.92
100%
Sold half or more
29 Mar 2021
Huang Jane CMO, Hematology
Sold, plan not stated 5×
$485.99K 1,500 at 324.00
100%
Sold half or more
26 Feb 2021
Huang Jane CMO, Hematology
Sold, plan not stated 5×
$481.10K 1,500 at 320.73
100%
Sold half or more
29 Jan 2021
Huang Jane CMO, Hematology
Sold, plan not stated 8×
$484.49K 1,500 at 322.99
100%
Sold half or more
15 Jan 2021
Liang Howard CFO & Chief Strategy Officer
Sold, plan not stated 2×
$4.35M 12,600 at 344.90
100%
Sold half or more
14 Jan 2021
Liang Howard CFO & Chief Strategy Officer
Sold, plan not stated 2×
$482.26K 1,400 at 344.47
100%
Sold half or more
4 Jan 2021
BAKER BROS. ADVISORS LP Director · indirect
Sold, plan not stated 2×
$26.71M 121,154 at 220.50
11.1%
29 Dec 2020
Huang Jane CMO, Hematology
Sold, plan not stated 6×
$373.69K 1,500 at 249.13
100%
Sold half or more
14 Dec 2020
Liang Howard CFO & Chief Strategy Officer
Sold, plan not stated 10×
$21.05M 91,900 at 229.04
100%
Sold half or more
4 Dec 2020
BAKER BROS. ADVISORS LP Director · indirect
Sold, plan not stated 2×
$333.30M 1,511,546 at 220.50
60.7%
Sold half or more
30 Nov 2020
Huang Jane CMO, Hematology
Sold, plan not stated 11×
$401.72K 1,500 at 267.82
100%
Sold half or more
29 Oct 2020
Huang Jane CMO, Hematology
Sold, plan not stated 3×
$450.09K 1,500 at 300.06
100%
Sold half or more
16 Oct 2020
Wang Xiaodong Director · indirect
Sold, plan not stated
$1.60M 5,000 at 320.00
100%
Sold half or more
5 Oct 2020
Liang Howard CFO & Chief Strategy Officer
Sold, plan not stated 11×
$4.19M 14,000 at 299.60
100%
Sold half or more
5 Oct 2020
Wang Xiaodong Director · indirect
Sold, plan not stated
$1.50M 5,000 at 300.00
100%
Sold half or more
5 Oct 2020
Wu Xiaobin President & GM China
Sold, plan not stated
$1.20M 4,000 at 300.00
100%
Sold half or more
29 Sep 2020
OYLER JOHN Chief Executive Officer
Sold, plan not stated 10×
$6.54M 23,303 at 280.82
100%
Sold half or more
29 Sep 2020
Huang Jane CMO, Hematology
Sold, plan not stated 4×
$420.57K 1,500 at 280.38
100%
Sold half or more
28 Sep 2020
OYLER JOHN Chief Executive Officer
Sold, plan not stated 5×
$8.68M 31,000 at 280.07
100%
Sold half or more
25 Sep 2020
Wang Xiaodong Director · indirect
Sold, plan not stated 2×
$1.40M 5,000 at 280.42
100%
Sold half or more
25 Sep 2020
Wu Xiaobin President & GM China
Sold, plan not stated
$1.12M 4,000 at 280.35
100%
Sold half or more
17 Sep 2020
Wang Xiaodong Director · indirect
Sold, plan not stated 2×
$1.30M 5,000 at 260.27
100%
Sold half or more
17 Sep 2020
Wu Xiaobin President & GM China
Sold, plan not stated 2×
$1.04M 4,000 at 260.33
100%
Sold half or more
16 Sep 2020
OYLER JOHN Chief Executive Officer
Sold, plan not stated 5×
$6.95M 27,275 at 254.77
100%
Sold half or more
15 Sep 2020
OYLER JOHN Chief Executive Officer
Sold, plan not stated 7×
$8.70M 34,214 at 254.26
100%
Sold half or more
14 Sep 2020
OYLER JOHN Chief Executive Officer
Sold, plan not stated 6×
$4.94M 19,739 at 250.25
100%
Sold half or more
14 Sep 2020
Liang Howard CFO & Chief Strategy Officer
Sold, plan not stated 6×
$3.50M 14,000 at 250.27
100%
Sold half or more
3 Sep 2020
Huang Jane CMO, Hematology
Sold, plan not stated 4×
$729.05K 3,128 at 233.07
100%
Sold half or more
2 Sep 2020
OYLER JOHN Chief Executive Officer
Sold, plan not stated 10×
$6.37M 27,807 at 229.22
100%
Sold half or more
1 Sep 2020
OYLER JOHN Chief Executive Officer
Sold, plan not stated 9×
$4.74M 20,274 at 233.79
100%
Sold half or more
31 Aug 2020
OYLER JOHN Chief Executive Officer
Sold, plan not stated 6×
$3.12M 12,961 at 240.86
100%
Sold half or more
28 Aug 2020
Huang Jane CMO, Hematology
Sold, plan not stated 5×
$726.63K 3,000 at 242.21
100%
Sold half or more
21 Aug 2020
OYLER JOHN Chief Executive Officer
Sold, plan not stated 7×
$9.80M 40,788 at 240.19
100%
Sold half or more
20 Aug 2020
OYLER JOHN Chief Executive Officer
Sold, plan not stated 8×
$5.05M 21,523 at 234.62
100%
Sold half or more
19 Aug 2020
OYLER JOHN Chief Executive Officer
Sold, plan not stated 6×
$7.01M 29,866 at 234.56
100%
Sold half or more
14 Aug 2020
OYLER JOHN Chief Executive Officer
Sold, plan not stated 5×
$1.84M 8,705 at 211.15
100%
Sold half or more
13 Aug 2020
OYLER JOHN Chief Executive Officer
Sold, plan not stated 6×
$3.10M 14,443 at 214.48
100%
Sold half or more
12 Aug 2020
OYLER JOHN Chief Executive Officer
Sold, plan not stated 6×
$4.20M 19,820 at 212.10
100%
Sold half or more
12 Aug 2020
Sold, plan not stated
$614.16K 2,897 at 212.00
100%
Sold half or more
11 Aug 2020
Sold, plan not stated 3×
$405.41K 1,903 at 213.04
100%
Sold half or more
10 Aug 2020
Wang Xiaodong Director · indirect
Sold, plan not stated 6×
$844.23K 4,000 at 211.06
100%
Sold half or more
10 Aug 2020
Sold, plan not stated 5×
$470.89K 2,200 at 214.04
100%
Sold half or more
5 Aug 2020
OYLER JOHN Chief Executive Officer
Sold, plan not stated 9×
$3.85M 17,254 at 223.27
100%
Sold half or more
4 Aug 2020
OYLER JOHN Chief Executive Officer
Sold, plan not stated 10×
$3.39M 15,383 at 220.43
100%
Sold half or more
3 Aug 2020
OYLER JOHN Chief Executive Officer
Sold, plan not stated 10×
$5.58M 25,176 at 221.78
100%
Sold half or more
29 Jul 2020
Huang Jane CMO, Hematology
Sold, plan not stated 5×
$629.79K 3,000 at 209.93
100%
Sold half or more
22 Jul 2020
OYLER JOHN Chief Executive Officer
Sold, plan not stated 13×
$6.61M 27,748 at 238.34
100%
Sold half or more
21 Jul 2020
OYLER JOHN Chief Executive Officer
Sold, plan not stated 8×
$6.65M 26,413 at 251.83
100%
Sold half or more
Showing 251–300 of 455. ← Newer Page 6 of 10 Older →